GLSI - Greenwich LifeSciences presents 5 year data for GP2 Phase IIb trial at SABCS

Greenwich LifeSciences (NASDAQ:GLSI) announces the publication of the GP2 Phase IIb clinical trial at the San Antonio Breast Cancer Symposium 2021 (SABCS). The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did not receive trastuzumab after surgery. A Delayed-Type Hypersensitivity (DTH) reaction was used to assess baseline in vivo immune responses to GP2 in patients prior to exposure to GP2 treatment or placebo. It was observed that 22.8% of the 145 patients reacted to GP2 at baseline with a positive immune response, which is defined as an induration of 5 mm or greater in the baseline DTH test. This new GP2 specific T cell data suggests that patients with a positive baseline immune response to GP2 recurred twice as fast and ~7 to 11 months sooner than those without a positive baseline immune response did. "To further diversify our

For further details see:

Greenwich LifeSciences presents 5 year data for GP2 Phase IIb trial at SABCS